SSAT067 PK of atazanavir/cobicistat and darunavir/cobicistat
Research type
Research Study
Full title
Pharmacokinetics of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours following drug intake cessation in healthy volunteers
IRAS ID
184771
Contact name
Marta Boffito
Contact email
Sponsor organisation
St Stephens AIDS Trust
Eudract number
2015-002956-28
Duration of Study in the UK
0 years, 5 months, 10 days
Research summary
The purpose of this study is to look at the levels of three HIV medications: atazanavir, darunavir and cobicistat in the blood after drug intake has been stopped, in order to understand how long these drugs persist in the blood. The study will specifically look at blood levels of these three drugs after taking them every day for 10 days. Participants will take Evotaz (atazanavir and cobicistat) on a first stage and Rezolsta (darunavir and cobicistat) on a second stage.
If the participants decide to take part, the duration of the study will be up to 33 days plus a screening visit which will take place up to 28 days prior to the start of the study, and a follow up visit, which takes place 7 to 14 days after the last dose of study medication.
This study is not randomised which means that all participants will receive all study medications in the same order. The participant and the study doctor will know which study medications the participant is taking at all times during the study.REC name
London - Bloomsbury Research Ethics Committee
REC reference
15/LO/1596
Date of REC Opinion
19 Oct 2015
REC opinion
Further Information Favourable Opinion